A systematic review and meta-analysis of the efficacy and adverse events of azacitidine-plus-lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia 1.
CONCLUSIONS: The current study may serve as a preliminary data to suggest that the addition of LEN may offer incremental benefit to patients with high-risk MDS, AML and CMML. However, randomized-controlled studies that directly compare the efficacy and adverse events of AZA-plus-LEN regimen versus AZA monotherapy are still needed.
PMID: 31221030 [PubMed - in process]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chronic Leukemia | Hematology | Leukemia | Myelodysplastic Syndrome | Revlimid | Study | Toxicology